All TL1A articles
-
BusinessMerck & Co to buy immunology specialist Prometheus
$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions
$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions